Compare
Yubo International Biotech Ltd vs ADM Tronics Unlimited, Inc. vs Neuraxis, Inc vs Nuwellis, Inc.
| Latest fiscal year | Yubo International Biotech Ltd YBGJ | ADM Tronics Unlimited, Inc. ADMT | Neuraxis, Inc NRXS | Nuwellis, Inc. NUWE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.4K | $3.35M | $3.57M | $8.27M |
| Revenue growth (YoY) | +256.0% | +4.7% | +32.9% | -5.4% |
| Gross margin | 66.1% | 40.5% | 84.2% | 62.0% |
| Operating margin | n/m | -4.8% | -219.4% | -134.3% |
| Net margin | n/m | -3.0% | -218.5% | -211.9% |
| Net income | -$1.08M | -$100.4K | -$7.80M | -$17.52M |
| EPS (Diluted) | -$0.01 | $0.00 | -$0.95 | -$25.39 |
| Operating cash flow | -$842.8K | -$124.1K | -$6.43M | -$10.81M |
| Free cash flow | n/a | n/a | -$6.46M | -$10.90M |
| Cash & equivalents | $8.1K | $255.7K | $4.97M | $1.08M |
| Total assets | $847.1K | $1.83M | $6.40M | $6.12M |
| Total liabilities | $2.79M | $1.26M | $3.00M | $3.49M |
| Shareholders' equity | -$1.95M | $571.0K | $3.40M | $2.62M |
| Return on year-end equity | n/a | -17.6% | -229.5% | -667.7% |
| Shares outstanding | n/a | 67.59M | 10.65M | 1.69M |
Revenue, most recent five fiscal years
| Fiscal year | Yubo International Biotech Ltd | ADM Tronics Unlimited, Inc. | Neuraxis, Inc | Nuwellis, Inc. |
|---|---|---|---|---|
| Latest | $12.4K Ended 2025-12-31 | $3.35M Ended 2026-03-31 | $3.57M Ended 2025-12-31 | $8.27M Ended 2025-12-31 |
| 1 year earlier | $3.5K Ended 2024-12-31 | $3.20M Ended 2025-03-31 | $2.69M Ended 2024-12-31 | $8.74M Ended 2024-12-31 |
| 2 years earlier | $604.7K Ended 2023-12-31 | $2.97M Ended 2024-03-31 | $2.46M Ended 2023-12-31 | $8.86M Ended 2023-12-31 |
| 3 years earlier | $104.3K Ended 2022-12-31 | $3.68M Ended 2023-03-31 | $2.68M Ended 2022-12-31 | $8.54M Ended 2022-12-31 |
| 4 years earlier | $1.24M Ended 2021-12-31 | $3.21M Ended 2022-03-31 | n/a | $7.92M Ended 2021-12-31 |